<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02849184</url>
  </required_header>
  <id_info>
    <org_study_id>4305-063</org_study_id>
    <nct_id>NCT02849184</nct_id>
  </id_info>
  <brief_title>To Compare the Effectiveness of Suvorexant vs Placebo on Sleep Pressure in Hypertensives With Insomnia</brief_title>
  <acronym>Super1</acronym>
  <official_title>A Multi-center, Double-blind, Randomized, Parallel Design Study to Compare the Effectiveness of Suvorexant Versus Placebo on Sleep Pressure and Circadian Rhythm in Hypertensives With Insomnia: The Super 1 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jichi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Satt Co.,Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jichi Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness and safety of suvorexant versus
      placebo on sleep pressure and circadian rhythm in hypertensives with insomnia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a 4-week run-in period and a 2-week treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 17, 2017</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of sleep systolic blood pressure</measure>
    <time_frame>2 weeks</time_frame>
    <description>To compare the efficacy of suvorexant versus placebo on the reduction of sleep systolic blood pressure (SBP) by ambulatory blood pressure monitoring (ABPM).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from non-dippers to dippers</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of morning systolic blood pressure variability</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the total sleep time</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the time to sleep onset</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of changes of sleep BP parameters with changes of sleep quality parameters</measure>
    <time_frame>2 weeks</time_frame>
    <description>Sleep BP parameters are measured by ambulatory blood pressure monitoring. Sleep quality is measured by self-reported sleep diary (satisfaction level of sleep).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of changes of urinary albumin-to-creatinine ratio (UACR) / NT-proBNP</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Hypertension</condition>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>suvorexant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>suvorexant</intervention_name>
    <description>Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.</description>
    <arm_group_label>suvorexant</arm_group_label>
    <other_name>Belsomra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily before bedtime.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        [At interim registration]

        Patients who meet the following criteria are eligible for the study:

          1. Patients who give written consent of agreement to voluntarily participation in the
             clinical study

          2. Age 20 years or older

          3. Sex: Male or female

          4. Treatment classification: Outpatient

          5. Hypertensive patient who meet at least one of the following:

               -  Under antihypertensive medications

               -  Clinic systolic blood pressure (SBP) less than 160 mmHg

          6. Patients with insomnia who meet at least one of the following:

               -  Patients with any one of the following symptoms twice a week or more and at least
                  1 month-continuation: difficulty initiating sleep (time to sleep onset 2 hours or
                  more longer than usual), difficulty maintaining sleep (awakening twice or more in
                  the night), early morning awakening (awakening 2 hours or more earlier in the
                  morning than usual), difficulty sleeping deeply (no soundly asleep feeling at the
                  time of awakening in the morning).

                  b. Patients with interference with social or occupational function due to the
                  above insomnia symptoms

        [At official registration]

        Patients who meet the following criteria at the end of run-in period are eligible for the
        study:

          1. Stable unchanged antihypertensive medication for run-in period.

          2. Average morning home SBP more than 135 mmHg during 5 days before the end of run-in
             period.

        Exclusion Criteria:

          1. Patients with serious liver disease.

          2. Patients with serious respiratory disease.

          3. Patients with secondary hypertension

          4. Patients with sleep apnea syndrome

          5. Patients with history of narcolepsy or cataplexy

          6. Patients with history of organic cerebral disorders

          7. Patients with history of hypersensitivity to suvorexant

          8. Patients received CYP3A strongly-inhibitors including itraconazole, clarithromycin and
             ritonavir, saquinavir, nelfinavir, indinavir, telaprevir and voriconazole at the start
             of the run-in period

          9. Patients with average clinic SBP of 160 mmHg or more at the start of the run-in period

         10. Patients received suvorexant and other hypnotic at the start of the run-in period on a
             regular basis

         11. Patients who are breast-feeding, pregnant, possibly pregnant, or plan to become
             pregnant

         12. Patients who are considered not to be eligible for this study by their investigator or
             sub-investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazuomi Kario, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jichi Medical University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Takahira Internal Medicine Clinic</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamasaki family clinic</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yagi hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2016</study_first_posted>
  <last_update_submitted>March 25, 2018</last_update_submitted>
  <last_update_submitted_qc>March 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jichi Medical University</investigator_affiliation>
    <investigator_full_name>Kazuomi Kario</investigator_full_name>
    <investigator_title>Professor &amp; Chairman, Division of Cardiovascular Medicine, Department of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

